Loading candles…
Krebs Biochemicals & Industries Ltd, incorporated in 1991, operates as a subsidiary of IPCA Laboratories Limited and receives strategic and financial support from its parent company. The company is engaged in manufacturing active pharmaceutical ingredients and intermediates through fermentation and chemical synthesis processes primarily within the biotechnology and pharmaceutical industries. It operates two manufacturing facilities located in Andhra Pradesh, India. Over recent years, Krebs Biochemicals & Industries Ltd has faced challenges including plant closure orders issued by pollution control authorities and a persistent trend of financial losses during the last five years.
This page is a live market overview for KREBS BIOCHEMICALS & IND (KREBSBIO) on the NSE. As a listed security, KREBS BIOCHEMICALS & IND is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for KREBSBIO before placing trades on tick2trade.
As of the latest feed, KREBSBIO last traded at ₹56.9 on NSE, up ₹0.04 (0.07%) from the previous close of ₹56.86. Today's session range is ₹56.3 – ₹59.6, against a 52-week band of ₹38.33 – ₹82.49. Traded volume today stands at 3.82K shares.
The overview consolidates an interactive price chart with multiple time ranges, five-level bid and ask depth, recent market headlines, upcoming corporate events for KREBSBIO in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether KREBSBIO is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for KREBS BIOCHEMICALS & IND before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in KREBSBIO. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated KREBSBIO option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters | 6 Aug 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and other business matters | 21 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 and other business matters | 9 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 and other business matters | 4 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters | 7 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and other business matters | 20 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.